Drug intelligence / Profile preview

PTC-2112

Development stage: Preclinical
Lead developer: Gerotherapeutix
Modality: Small Molecules

Overview

PTC-2112 is a preclinical small molecule candidate developed by Gerotherapeutix (a subsidiary of Eos Senolytix) for the treatment of obesity and glucose metabolic disorders. It is part of the MitoXcel™ Ouropeptide program, which focuses on systemic rejuvenation and longevity by targeting mitochondrial health. The drug's mechanism of action involves the modulation of mitochondrial membrane potential (MMP/ΔΨm), specifically categorized by the developer as 'Mechanism 1'. PTC-2112 is designed to address metabolic dysfunction associated with aging and obesity by optimizing mitochondrial bioenergetics and restoring cellular homeostasis.

Other names: MitoXcel Ouropeptide

Beyond the preview

Go deeper on PTC-2112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTC-2112.

Explore the full profile